Disc Medicine, Inc.

As of June 30, 2026, Disc Medicine, Inc. carries a market capitalization of 2.80B, placing it among publicly traded companies globally. Its enterprise value stands at 2.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Disc Medicine, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Disc Medicine, Inc. has 38.35M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Disc Medicine, Inc. maintains a current ratio of 24.14, meaning it holds 24.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.45, indicating elevated leverage, while an interest coverage ratio of -75.71 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Disc Medicine, Inc. posted a negative return on equity (ROE) of -39.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.12, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 137.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Disc Medicine, Inc. recorded 310,000.00 in income tax expense. The company reported a pretax loss of -245.58M and -245.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Disc Medicine, Inc.'s stock has declined approximately 13.98% over the past 52 weeks. The 50-day moving average sits at 71.35, while the 200-day moving average is 70.64.

Over the twelve months ended June 30, 2026, Disc Medicine, Inc. generated - - in revenue and converted that into -245.89M in net income, yielding earnings per share of -6.57. EBITDA reached -268.91M, while operating income came in at -269.26M.

As of June 30, 2026, Disc Medicine, Inc. holds 717.75M in cash and equivalents against 60.86M in total debt, resulting in a net debt position of -39.34M. Total book value stands at 644.16M, with working capital of 702.40M providing operational flexibility.

Disc Medicine, Inc. produced -197.54M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -46,000.00 in capital expenditures, free cash flow totaled -197.58M - equivalent to -5.28 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.35, meaning Disc Medicine, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Disc Medicine, Inc.'s most recent stock split took place on December 30, 2022 with a 10:1 split ratio.

As of June 30, 2026, Disc Medicine, Inc. has an Altman Z-Score of 17.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.